304 related articles for article (PubMed ID: 17549824)
1. Evolving issues in male hypogonadism: evaluation, management, and related comorbidities.
Miner MM; Sadovsky R
Cleve Clin J Med; 2007 May; 74 Suppl 3():S38-46. PubMed ID: 17549824
[TBL] [Abstract][Full Text] [Related]
2. Testosterone deficiency in older men: a problem worth treating.
McHenry Martin C
Consult Pharm; 2012 Mar; 27(3):152-63. PubMed ID: 22421515
[TBL] [Abstract][Full Text] [Related]
3. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin S; Brito JP; Cunningham GR; Hayes FJ; Hodis HN; Matsumoto AM; Snyder PJ; Swerdloff RS; Wu FC; Yialamas MA
J Clin Endocrinol Metab; 2018 May; 103(5):1715-1744. PubMed ID: 29562364
[TBL] [Abstract][Full Text] [Related]
4. Current topics in testosterone replacement of hypogonadal men.
Nieschlag E
Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):77-90. PubMed ID: 25617174
[TBL] [Abstract][Full Text] [Related]
5. Testosterone therapy has positive effects on anthropometric measures, metabolic syndrome components (obesity, lipid profile, Diabetes Mellitus control), blood indices, liver enzymes, and prostate health indicators in elderly hypogonadal men.
Canguven O; Talib RA; El Ansari W; Yassin DJ; Salman M; Al-Ansari A
Andrologia; 2017 Dec; 49(10):. PubMed ID: 28295504
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
7. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?
Gould DC; Kirby RS
Prostate Cancer Prostatic Dis; 2006; 9(1):14-8. PubMed ID: 16264770
[TBL] [Abstract][Full Text] [Related]
8. EMAS position statement: Testosterone replacement therapy in the aging male.
Dimopoulou C; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; van der Schouw YT; Senturk LM; Simonsini T; Stevenson JC; Stute P; Goulis DG
Maturitas; 2016 Feb; 84():94-9. PubMed ID: 26614257
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
10. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men.
Lunenfeld B; Mskhalaya G; Zitzmann M; Arver S; Kalinchenko S; Tishova Y; Morgentaler A
Aging Male; 2015 Mar; 18(1):5-15. PubMed ID: 25657080
[TBL] [Abstract][Full Text] [Related]
11. Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations.
Yeap BB; Grossmann M; McLachlan RI; Handelsman DJ; Wittert GA; Conway AJ; Stuckey BG; Lording DW; Allan CA; Zajac JD; Burger HG
Med J Aust; 2016 Sep; 205(5):228-31. PubMed ID: 27581270
[TBL] [Abstract][Full Text] [Related]
12. Point: urologists should take an active role in the diagnosis and treatment of hypogonadism in the aging male.
Heaton JP
Can J Urol; 2002 Dec; 9(6):1677-80. PubMed ID: 12517308
[TBL] [Abstract][Full Text] [Related]
13. Testosterone replacement in men.
Beg S; Al-Khoury L; Cunningham GR
Curr Opin Endocrinol Diabetes Obes; 2008 Aug; 15(4):364-70. PubMed ID: 18594278
[TBL] [Abstract][Full Text] [Related]
14. An Overview of Testosterone Therapy.
Lee OD; Tillman K
Am J Mens Health; 2016 Jan; 10(1):68-72. PubMed ID: 25398416
[TBL] [Abstract][Full Text] [Related]
15. The role of accurate testosterone testing in the treatment and management of male hypogonadism.
Dobs AS
Steroids; 2008 Dec; 73(13):1305-10. PubMed ID: 18639568
[TBL] [Abstract][Full Text] [Related]
16. Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review.
Hellstrom WJ; Paduch D; Donatucci CF
Int Urol Nephrol; 2012 Feb; 44(1):61-70. PubMed ID: 21152980
[TBL] [Abstract][Full Text] [Related]
17. [Testosterone replacement treatment in older people with and without co-morbidities].
Zitzmann M
Internist (Berl); 2020 Jun; 61(6):549-557. PubMed ID: 32377774
[TBL] [Abstract][Full Text] [Related]
18. Testosterone replacement therapy in men with type 2 diabetes mellitus and functional hypogonadism -an Integrated Diabetes and Endocrine Academy (IDEA) consensus guideline.
Majumdar S; Mukherjee JJ; Ray S; Goswami S; Jude E; Biswas A; Hanumanthu A; John M; Sinha B; Ghoshal S; Kota S; Sharma SK; Jacob JJ
Diabetes Metab Syndr; 2021; 15(4):102191. PubMed ID: 34245961
[TBL] [Abstract][Full Text] [Related]
19. MANAGEMENT OF ENDOCRINE DISEASE: Rationale and current evidence for testosterone therapy in the management of obesity and its complications.
Lapauw B; Kaufman JM
Eur J Endocrinol; 2020 Dec; 183(6):R167-R183. PubMed ID: 33105105
[TBL] [Abstract][Full Text] [Related]
20. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy.
Yeap BB; Grossmann M; McLachlan RI; Handelsman DJ; Wittert GA; Conway AJ; Stuckey BG; Lording DW; Allan CA; Zajac JD; Burger HG
Med J Aust; 2016 Aug; 205(4):173-8. PubMed ID: 27510348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
